Table 2: Clinical trials of rectal cancer [78].

Study	Key inclusion criteria	Treatment	Outcomes
Ngan, et al. [71]	T3,T4	RT short course and immediate surgery RT long course and delayed surgery	DFS: 67% vs. 66% Recurrence: 9% vs. 14.2%
Van Djk, et al. [79]	Stage IV	RT short course + CAPOX + Bebazizumab	pCR: 26%
Tunio, et al. [80]	T4	RQnt QT with capecitabineT + neoadyuv	pCR: 85.4%
Bujko, et al. [70]	Stage IV	NUeoadyuvant RT short course + FOLFOX vs. QRT with 5-F	pCR: 21% vs. 9%
Garcia-Aguilera	T3,T4	RT with 5 FU RT with 5 FU followed by FOLFOX x 4 weeks	pCR: 18% vs. 25%

DFS: Disease Free Survival, pCR: Pathologic Complete Response